Core Viewpoint - Jinling Pharmaceutical announced that its subsidiary Chizhou Dongsheng Pharmaceutical has received approval from the National Medical Products Administration for the registration of potassium sulfate, which is a raw material for oral solutions used for bowel cleansing before medical procedures. This approval indicates that the raw material meets domestic drug registration requirements and can be produced and sold in the domestic market, enhancing the company's product line in raw materials. However, production and sales will take time, and it will not have a significant impact on the company's current performance [1]. Summary by Relevant Categories - **Regulatory Approval**: The approval for potassium sulfate registration has been granted by the National Medical Products Administration, allowing for its production and sale in the domestic market [1]. - **Product Line Expansion**: This approval will enrich the company's raw material product line, providing more options for its offerings [1]. - **Impact on Performance**: The company indicates that the production and sales of potassium sulfate will take time, and therefore, it will not significantly affect the company's current financial performance [1].

四川合纵药易购医药股份有限公司(证券代码：300937)于2025年8月11日发布半年报。报告显示，公司 当期实现营业收入 21.57 亿元。虽较上年同期略有波动，但结合市场情况与行业综合来看符合市场预 期。本期报告中显示药易购长期价值生态版图已十分清晰，核心业务结构性优化与创新赛道突破为中长 期发展奠定坚实基础。 下游：全域触达激活 C 端价值 线上，重庆药大麦 2025 年上半年收入 1.5 亿元，达 2024 年全年的 77.73%，"伟哥" 系列产品在电商平 台处方药类目 GMV 排名第一;玉鑫中医世家作为拼多多 "十大国民健康品牌"，中成药占比超 80%，复 购率达 68%，全域粉丝超 100 万。线下，通过控股 / 参股 451 家连锁药店(含 1474 家加盟店)，结合 O2O 无人智能药仓，在成都实现 "9 分钟达" 即时配送，O2O 订单量增长 67%。 产业链上下游布局、数智化生态构建、C 端全域触达等核心战略领域的投入持续加码，以全渠道供应链 为核心，以数智创新技术为加速，通过人才与资本加速发展的战略路径逐渐明朗，"医药+科技"、"平台 +生态"、"自营+赋能"的核心定位正加速成型。短期 ...